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Subjects
This study was a prospective cohort study recruiting adult newly diagnosed TB patients from Public Health Centers in Yogyakarta and Lampung. The inclusion criteria were newly diagnosed of TB patients. The diagnose of TB used the result of sputum test which showed the positive result for Acis-Fast Bacili (AFB) and X-ray results, were treated with fixed-dose combination of anti-TB drugs dosed according to the WHO guidelines, [3] and had normal function of the kidney and liver at the baseline measurement. The exclusion criteria were participants fulfilled the inclusion criteria who are having human immunodeficiency virus and/or diabetes mellitus history, liver abnormality history, abnormality of the renal and/or liver function, and reactive results of hepatitis B surface antigen test.
According to the WHO, DILI was defined as a level of alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) of at least 3.0 the upper limited number. [4, 5] The normal ranges of ALT and AST in the Indonesian population are <31 U/L and 3-45 U/L, respectively, using the kinetic method of the International Federation of Clinical Chemistry assay. [6, 7] 
DNA collection
The DNA was taken from the patients' saliva using an Oragene DNA collection kit (DNA Genotek, Ottawa, Canada) and all the samples were purified using GlycoBlue Coprecipitant (Thermo Fisher Scientific, Waltham, USA). The quality of DNA was verified by NanoDrop TM spectrophotometer measurement.
Single-nucleotide polymorphisms identification
This study defined the following single-nucleotide polymorphisms (SNPs): rs1799929, rs1799930, rs1799931, rs1801280, and rs1041983 of NAT2; rs2031920, rs8192775, and rs2515641 of CYP2E1; rs1041981, rs1063355, and rs6906021 of HLA, according to the previous studies. [8] [9] [10] Genotyping was performed with the MassARRAY iPlex pro system (Agena BioScience, San Diego, USA). The NAT2 was phenotyped into extensive, intermediate, and slow acetylators according to the function of the allele of the SNPs used in this study. [11, 12] GSTT1 and GSTM1 were defined as GSTT1, GSTM1, and GSTT1 deletion and GSTM1 deletion. PCR was carried out according to the literature, [13] using PrimeSTAR Polymerase (TAKARA BIO INC., Shiga, Japan). PCR products were analyzed by 0.8% agarose gel electrophoresis. The presence of the deletion and the presence of the gene were tested separately because of their difference in fragments length (625 and 969 bp for the genes and 3106 and 4748 bp for the deletions, respectively).
Antituberculosis drug plasma concentration
Data of anti-TB drug plasma concentration on the weeks 4-8 of the treatment were retrieved from the patients' medical report. Plasma samples had been collected in 57 TB patients, 2 h after administration of the drug in fasted condition. [6, 7, 14, 15] The samples were processed after sample collection and subsequently stored in the frozen condition until routine analysis. The method has been validated previously. [16, 17] The mixed solution was vortexed for 15 s and was centrifuged for 10 min at 10,000 rpm. The supernatant was taken from the solution and was used for the next process. Ether (3 ml) was added to 100 μL of the supernatant, and the water phase was taken. The 20 μL water phase was injected into the high-performance liquid chromatography system. The accuracy and the intraday-interday precisions met the criteria from the US Department of Health and Human Services Food and Drug Administration. [18] We defined the normal range of Isoniazid, Rifampicin, Pirazinamide, Ethambutol (HRZE) as 3-6 μg/ ml, 8-24 μg/ml, 20-50 μg/ml, and 2-6 μg/ml, respectively. [14] 
Data analysis
Data were analyzed using Chi-square test, Student's t-test, and multivariate analysis. Multinomial logistic regression was performed among phenotype of NAT2, GSTT1, GSTM1, rs2031920 (CYP2E1), rs2515641 (CYP2E1), rs8192775 (CYP2E1), rs1041981 (HLA), rs1063355 (HLA), and rs6906021 as independent variables and DILI as a dependent variable.
results

Patients' characteristics
In total, 232 newly diagnosed adult TB patients from Yogyakarta and Lampung were screened and 207 met inclusion criteria and were recruited. Patient characteristics are shown in Table 1 . Most of the patients were female (60.6%), with a mean age of 40.7 (standard deviation: 14.8). Most of the patients had a positive result of the AFB test (85%) and around 57% of them were underweight. The average of body mass index was also in underweight condition (18.3) . Only around 8% of the patients had comorbidities or disease history and Type 2 diabetes mellitus was the most prevalent comorbidity in this study (4.0%).
Hepatotoxicity
Increased ALT and AST was predominantly observed in the 2 nd month of TB treatment [ Table 2 ]. In total, 1.0%, 1.9%, and 1.0% of the TB patients experienced mild DILI based on increased ALT, AST, and ALT-AST, respectively. The occurrence of DILI was not associated with any of the patients' characteristics (data were not shown: P > 0.05) [ Table 1 ].
Single-nucleotide polymorphisms characteristics and association with hepatotoxicity
The NAT2 genes are phenotyped into extensive (25.0%), intermediate (5.6%), and slow acetylators (69.5%). In CYP2E1, the CC of rs2031920, GG of rs8192775, and CC of rs2515641 had the highest percentages of the genotypes (72.2%, 72.4%, and 62.4%, respectively). The percentages of GSTT1 homozygous deletion and GSTM1 homozygous deletion are 9.4% and 21.6%, respectively. The percentages of GT of HLA-DQA*0102 and CC of HLA-DQB*0302 are the highest compared to the other genotypes (44% and 29%, respectively).
There were no significant associations between gene polymorphisms of CYP2E1, GSTT1, and GSTM1 and the risk of DILI. A significant association was found between the NAT2 phenotype and patients experiencing DILI. Patients with extensive acetylators phenotype did not experience DILI (odds ratio [OR]: 0.46; 95% confidence interval [CI]: 0.23-0.94). The authors find that T carriers of rs2515641, homozygous deletion of GSTM1, and TC carriers of HLA rs6906021 tend to be a predictor of DILI. The significant associations are also shown by G carriers of HLA rs1063355 which could protect the patients from the DILI (OR: 0.39; 95% CI: 0.14-0.9) and the C carriership of HLA rs1041981 which can also protect the patients from DILI (OR: 0.38; 95% CI: 0.15-0.50). Table 4 shows that only 13.9% of the patients had an isoniazid plasma concentration in the normal range; furthermore, 0.66%, 41.9%, and 2.90% of the patients had plasma concentration of ethambutol, pyrazinamide, and rifampicin, respectively, in the normal range. According to the therapeutic range, 99.3% and 70.2% of the patients had ethambutol and rifampicin concentrations under the normal range. About 79% of the patients had high isoniazid concentration (above the therapeutic range) and 53% had high pyrazinamide concentrations. According to the acetylator category, 86.3% slow acetylators had Isoniazid (INH) concentration higher than upper range concentration. This pattern also can be seen in the extensive acetylators patients, even though the proportion of patients is lower than slow acetylators.
Antituberculosis drug plasma concentration and association with single-nucleotide polymorphisms
According to the 57 data of isoniazid plasma concentration, only 37 patients experienced DILI. Table 5 presents the association between gene polymorphisms and isoniazid plasma concentration. Patients with high isoniazid plasma concentration have 2.6 times higher risk of experiencing DILI (95% CI; 0.5-13.1). The slow acetylators of NAT2 and homozygous deletion of GSTT1 and GSTM1 have a risk of having high isoniazid plasma concentration as amounting to 3.0, 1.1, and 1.36, respectively (95% CI: 0.7-20.7; 1.0-1.3; 0.2-9.1). Table 6 shows the significant difference in isoniazid concentration among the genotypes of HLA-DQB*0302. However, there is no significant difference in isoniazid concentration among the genotypes of HLA-DQA*0102 and rs1041981. The TC genotype has the highest isoniazid plasma concentration compared to CC and TT (P = 0.017). The isoniazid plasma concentrations in the TC genotype are above
The results of association analysis between the genes polymorphisms and DILI are presented in Table 3 . The highest percentages of genotypes which experienced DILI were 48.9% of slow acetylators of NAT2, 50% CC of rs2031920, 41.7% CC of rs2515641, and 66.4% G carrier of rs8192775 of CYP2E1. Among the GSTT1 and GSTM1, the highest percentages of DILI patients were seen in the homozygous wild-type and heterozygous, which are 62.6% and 51.4%, respectively. Moreover, among the HLA, the highest percentages of patients who experienced DILI were a presence on the G carriers of HLA-DQA*0102 (53.6%), CC and CT genotypes of HLA-DQB*0302 (41.7%), and C carriers of rs1041981 (35.4%). Multinomial logistic regression was performed among phenotype of NAT2, GSTT1, GSTM1, rs2031920 (CYP2E1), rs2515641 (CYP2E1), rs1041981 (HLA), rs1063355 (HLA), and rs6906021 as independent variables and DILI as a dependent variable. The authors found that G carriers of HLA-DQA*0102 have a protective effect against DILI compared to T carriers (OR: 0.38; 95% CI: 0.15-0.95).
dIscussIon
Our study showed that slow acetylators of the NAT2 phenotype are highly prevalent in this cohort of Indonesian patients. There are some variations in the genotypes of CYP2E1 in rs2031920, rs8192775, and rs2515641. Furthermore, the GSTM1 homozygous deletion is predominant in the study population. The variations of HLA-DQA*0102 and HLA* DQB0302 are also available.
A statistically significant association with genetic variants was found between DILI and NAT2 phenotype and G carriers This finding is also supported by the previous meta-analysis of 13 randomized studies with rapid and slow acetylators. The rapid acetylators may predict the treatment failure, the absence of ADR, and relapse possibility. This study also suggested that the treatment failure and ADR were significantly associated with the pharmacokinetics of this single drug in the combination. [19] Even though the significant associations were only presented between the NAT2 and DILI, our study showed that some variations of the gene may predict the incidence of DILI, such as the slow acetylators of NAT2, T carrier of CYP2E1 rs2516451, and homozygous deletion of GSTM1, which are related to the higher number of patients with DILI. These results are also supported by the high plasma concentrations of INH in the slow acetylators of NAT2, T carrier of CYP2E1 rs2516451, and homozygous deletion of GSTM1. The previous study in Japan about the NAT2 genotype-guided regimen presented that 78% patients with standard treatment of TB experienced DILI; however, none of the patients with pharmacogenetic screening-guided treatment experienced DILI or failure of the treatment. [20] Regarding the INH concentration, both slow and extensive acetylators showed the high concentration exceeds the upper limit of INH's range concentration. Remarkably, the proportion of patients with the high concentration of INH in the slow acetylators group was higher than the extensive acetylators group. These results were also supported by the previous study conducted in India. TB patients with slow acetylators had higher concentrations of INH than patients with intermediate and rapid acetylators and the INH concentration among the three groups was significantly different. India's study also presented that patients with slow, intermediate, and rapid acetylators had lower INH concentration, which was <3 μg/ml. [21] The presence of slow acetylators of NAT2 (37%) in Colombian Caribbean Coast region which may predict the DILI was consistent with our study results. [22] The Chinese population also showed similar results of slow acetylators of NAT2 which had higher risk of DILI. [23] Our study is also supported by another previous study in Thai populations. The slow acetylators had a higher frequency of DILI than the immediate and rapid acetylators in the group of patients. However, in the control group, the intermediate acetylators had the highest frequency. [24] This confirmed earlier results showing that slow acetylators of NAT2 both in Asian and non-Asian population had higher risk of DILI. [25] In the Moroccan population, the frequency of c1/c1 of CYP2E1 rs2031920 was around 98%, also in the other populations such as Turkish, Germanians, Serbians, French, English, and Brazilians. However, the frequency of c1/c1 of CYP2E1 rs2031920 in Taiwanese and Chinese was around 50%. These results are different from our study which shows that the percentage of the CC genotype of CYP2E1 rs2031920 reaches 70% and the T carriers of this SNP had a risk of having high isoniazid plasma concentration. Contradictorily, according to the meta-analysis of the CYP2E1 rs2031920, the c1/c1 genotype was related to DILI, especially in the Chinese and Korean population. [26] In the Indian population, the risk of DILI did not associate with the polymorphisms of rs2031920 of CYP2E1. [8] Our current study shows that the homozygous deletion of GSTM1 needs to be explored further to predict the DILI in the Indonesian population. This result is supported by some previous studies, such as in children in the Chinese Han population; the GSTT1 and GSTM1 did not correlate with DILI and the age was more associated with DILI. [27] According to a meta-analysis, the East Asian, including Chinese population with the null genotypes of GSTM1 experienced an increase of DILI risk. However, the null genotypes of GSTT1 did not have an association with the DILI in patients receiving isoniazid, rifampicin, pyrazinamide, and ethambutol. [10, 28] The HLA gene was supposed to have a correlation with the incidence of pulmonary TB due to the immunity mechanism. In some specific areas in India, some haplotypes of HLA were found in pulmonary TB patients. [9, 29] Our study found that the G carriers of HLA-DQA*0102 had more protection to the DILI, although the H-concentrations were not associated with the genotype. This finding is supported by a previous study in North Indian which stated that the absence of HLA-DQA*0102 and the presence of HLA-DQB1*0201 became the independent factor of ATDH. [9] To the best of the authors' knowledge, the significant difference of isoniazid plasma concentration among the genotype of HLA-DQB*0302, although not accompanied by associations with DILI is a new finding in the Indonesian population.
The limited sample size and limited pharmacokinetic assessment by measuring only C2 concentrations are important limitations of our study. An increased sample size number in combination with a full pharmacokinetic curve allowing correlation with actual Cmax and AUC will likely increase the statistical power.
conclusIon
We conclude that in the Indonesian population, the NAT2 genotype, but not the CYP2E1, GSTM, and GSTT1 genotype, is significantly associated with DILI. Furthermore, the absence of HLA-DQA*0102 could protect the patients from DILI without being associated with an effect on the H-concentration in contrast to the NAT2 genotype. C carriership of HLA-DQB*0302 is significantly associated with increased H-concentrations, but not with DILI.
